2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
2021 · Blood · 681 citations
https://doi.org/10.1182/blood.2021013626
V
Veit Bücklein
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
158
Papers
3.5K
Citations
31
h-index
48
i10-index
Veit Bücklein is an academic researcher from Ludwig-Maximilians-Universität München. The author has contributed to research in topics: CAR-T cell therapy research & Acute Myeloid Leukemia Research & Hematopoietic Stem Cell Transplantation. The author has an h-index of 31, co-authored 135 publications.
ORCID: 0000-0001-7391-7280Papers by this author
worksT-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
2022 · Blood · 215 citations
https://doi.org/10.1182/blood.2022015956
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2019 · Blood · 86 citations
https://doi.org/10.1182/blood-2019-127977
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy
2022 · European Journal of Nuclear Medicine and Molecular Imaging · 22 citations
https://doi.org/10.1007/s00259-022-06075-2
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
2022 · Biomarker Research · 19 citations
https://doi.org/10.1186/s40364-022-00390-4
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
2024 · Leukemia · 8 citations
https://doi.org/10.1038/s41375-023-02127-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat